. Author manuscript; available in PMC: 2019 Dec 13.

Published in final edited form as: J Med Chem. 2018 Nov 30;61(23):10910–10921. doi: 10.1021/acs.jmedchem.8b01671

Table 2. Comparative pharmacokinetic parameters.

Balb/c mice, single oral dose 25 mg/kg

Cmpds	Plasma		Tissue distribution, 4 hours after administration, μM (±SEM), n=2
	C_{p, max, μM}	Life time, hours^*	Liver	Heart	Lung	Spleen	Blood	Brain
VFV	24	>24	34 ± 6	16 ± 3	74 ± 25	21 ± 7	22 ± 5	1 ± 0.2
VFV-Cl	13	16	20 ± 8	3 ± 3	18 ± 7	6 ± 2	12 ± 4	0.2
2	5	10	3 ± 0	0.1	0.6 ± 0	2 ± 1	1 ± 0.5	0.1
3	nd^**	nd	0.4	0.1	1 ± 1	nd	nd	nd
4	28	<10	21 ± 6	5 ± 0.2	8 ± 2	5 ± 1	9 ± 1	0.1
5	15	<16	17 ± 9	3 ± 0.5	26 ± 4	3 ± 2	4 ± 2	0.2
6	nd	nd	nd	nd	nd	nd	nd	nd
7	25	>24	120 ± 25^***	56 ± 10	57 ± 19	63 ± 37	25 ± 5	3 ± 1
8	7	6	32 ± 5	6 ± 1	38 ± 13	6 ± 2	3 ± 0.5	0.15
9	38	16	38 ± 2	36± 15	46 ± 7	28 ± 8	36 ± 6	8 ± 4

the time until the compound becomes undetectable;

^**

below 0.1 μM, which is the detection limit;

^***

high concentration of 7 in the liver might compensate for its relatively weaker stability in mouse liver microsomes (Table 1).